HIV-associated obstructive lung diseases: insights and implications for the clinician.
The effectiveness of antiretroviral therapy to control HIV infection has led to the emergence of an older HIV population who are at risk of chronic diseases. Through a comprehensive search of major databases, this Review summarises information about the associations between chronic obstructive pulmonary disease (COPD), asthma, and HIV infection. Asthma and COPD are more prevalent in HIV-infected populations; 16-20% of individuals with HIV infection have asthma or COPD, and poorly controlled HIV infection worsens spirometric and diffusing capacity measurements, and accelerates lung function decline by about 55-75 mL/year. Up to 21% of HIV-infected individuals have obstructive ventilatory defects and reduced diffusing capacity is seen in more than 50% of HIV-infected populations. Specific pharmacotherapy considerations are needed to care for HIV-infected populations with asthma or COPD-protease inhibitor regimens to treat HIV (such as ritonavir) can result in systemic accumulation of inhaled corticosteroids and might increase pneumonia risk, exacerbating the toxicity of this therapy. Therefore, it is essential for clinicians to have a heightened awareness of the increased risk and manifestations of obstructive lung diseases in HIV-infected patients and specific therapeutic considerations to care for this population. Screening spirometry and tests of diffusing capacity might be beneficial in HIV-infected people with a history of smoking or respiratory symptoms.
Division of Pulmonary, Critical Care and Sleep Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: mdrummo3@jhmi.edu.
M Bradley
MB
Drummond
Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Gregory D
GD
Kirk
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D001249:Asthma / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D036501:Metered Dose Inhalers; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D012907:Smoking / Q000453:epidemiology; D013147:Spirometry; D014109:Total Lung Capacity
D000305:Adrenal Cortex Hormones; D044966:Anti-Retroviral Agents